Intelligent microbiome team cooperates with the laboratory to develop "living biological drugs", targeting inflammatory bowel disease and diabetes microorganisms | strains | microbiome
In an adult's body, the number of gut microbiota can reach the 12th to 14th power of 10, with a total weight of approximately 2-3 pounds, equivalent to an organ in the human body. Scientific research has found that these microorganisms are closely related to human health and diseases. Recently, the School Enterprise Joint Laboratory of the Intelligent Microbiology Group was inaugurated in Shanghai Medical College of Fudan University. The Institute of Intelligent Medicine of Fudan University will cooperate with Shanghai Lishan Biomedical Co., Ltd. to develop living biological drugs using selected beneficial microbial strains for the treatment of inflammatory bowel disease, insulin resistance subtype 2 diabetes caused by intestinal disorders and other diseases.
Professor Liu Lei, Executive Vice Dean of the Institute of Intelligent Medicine at Fudan University, introduced that gut microbiome is a new track in international biopharmaceutical research. It breaks through the limitations of traditional biopharmaceuticals and explores the boundaries of innovative biopharmaceuticals through the deep learning of big data through cross disciplinary multi omics and artificial intelligence. "The addition of Lishan Pharmaceuticals this time will fill the cutting-edge gap in microbiology for the Institute of Intelligent Medicine at Fudan University."
Lishan Pharmaceutical has gathered a group of domestic and foreign scientists in the field of biomedicine, mainly focusing on gut microbiota live biopharmaceuticals. The company has integrated global intestinal microbiota technology resources and is collaborating with Fudan Intelligent Medical Research Institute to build an AI interdisciplinary new drug discovery platform, developing innovative drugs with international differentiation competitive advantages.
"After the completion of the Human Genome Project in 2003, countries and regions such as the United States, the European Union, China, and Japan launched the Human Microbiome Project. In recent years, based on this international scientific project, the market for live biopharmaceuticals targeting gut microbiota is emerging. Dr. Chen Weijie, Chairman of Lishan Pharmaceutical, told reporters that live bacterial therapy has opened up a new therapeutic revolution, especially in the treatment of inflammatory bowel disease, infection, and metabolic diseases.". This therapy neutralizes inflammation and metabolic signals produced by pathogens by introducing beneficial microorganisms into the human microbiota affected by the disease.
This Shanghai company utilizes multiple large-scale datasets established by the Human Microbiome Program, combined with artificial intelligence technology, to deeply explore the complexity of microbial community dynamics and individual differences in microbial communities. At present, the company has screened multiple beneficial microbial strains for inflammatory bowel disease, which has no specific drugs available and seriously reduces the quality of life of patients. It is conducting experiments on efficacy, toxicology, drug metabolism, and plans to launch IIT next year. For insulin resistance subtype 2 diabetes caused by intestinal disorder, the company has completed the mouse experiment of living biological drugs under research and is optimizing the CMC formula.
In the process of screening strains, Lishan Pharmaceutical collaborated with the Shanghai Institute of Immunology at Shanghai Jiao Tong University School of Medicine and the Institute of Intelligent Medicine at Fudan University. With the comprehensive research platforms of these two research institutions, artificial intelligence assisted prediction, selection, and validation of the efficacy and immunogenicity of the strains were carried out, achieving good results.
This collaboration between industry, academia, and research has also promoted the establishment of a school enterprise joint laboratory for intelligent microbial communities. Chen Weijie stated that the joint laboratory will contribute to breakthroughs in domestic gut microbiome research and narrow the gap between China and some developed countries in the field of microbiome. "We also believe that with the power of artificial intelligence, we will provide more effective solutions for the treatment of various diseases."
At the unveiling ceremony of the joint laboratory, Zhu Tongyu, Vice Dean of Shanghai Medical College and Dean of Intelligent Medicine Research Institute at Fudan University, Chu Yiwei, Secretary of the Party Committee of the Biomedical Research Institute at Fudan University, presented expert appointment letters to Professor Su Bing, Director of the Shanghai Institute of Immunology and Head of the Department of Immunology and Microbiology at Shanghai Jiao Tong University Medical College, Professor Ma Jianpeng, Dean of the Multi scale Research Institute of Complex Systems at Fudan University, Professor Ge Guangbo, Executive Vice Dean of the Cross disciplinary College of Shanghai University of Traditional Chinese Medicine, Professor Liu Lei, Executive Vice Dean of the Intelligent Medicine Research Institute at Fudan University, Professor Yin Weihai, Vice Dean of the Med-X Research Institute at Shanghai Jiao Tong University, and Professor Zhang Dachuan, Doctoral Supervisor at Shanghai Jiao Tong University School of Medicine.
As the Chairman of the Academic Committee of the Joint Laboratory, Professor Su Bing stated that the Academic Committee will innovate its research system and mechanism, collaborate with domestic and foreign universities and top research institutions, gather senior experts in various related fields, and build the Joint Laboratory into a leading research and development institution in intelligent microbiology in China.
